Identifying biomarkers and treatment strategies for peritoneal surface malignancies
Prospective Observational Study of Peritoneal Surface Malignancies (PSM) - Characterization, Models and Treatment Strategies.
This study is trying to find specific markers in patients with peritoneal surface cancers to help choose the best treatment options and improve their chances of recovery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Oslo University Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Oslo) |
| Trial ID | NCT02073500 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify biomarkers associated with disease recurrence and prognosis in patients with peritoneal surface malignancies (PSM) such as pseudomyxoma peritonei, colorectal carcinoma, ovarian carcinoma, and mesothelioma. The study will optimize patient selection for cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC). Utilizing a unique biobank and institutional database, along with novel animal models, the research team will explore various treatment strategies to improve outcomes for patients with limited disease. Approximately 80 patients per year will be included based on their eligibility for CRS-HIPEC.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old with a confirmed diagnosis of peritoneal surface malignancy who are eligible for CRS-HIPEC.
Not a fit: Patients with advanced disease that precludes them from being candidates for CRS-HIPEC may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved patient selection and treatment outcomes for individuals with peritoneal surface malignancies.
How similar studies have performed: Other studies have shown promise in using biomarkers for patient selection in similar treatment approaches, indicating a potential for success in this area.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * age \> 18 years * confirmed diagnosis of peritoneal surface malignancy * candidate for CRS-HIPEC * written informed consent Exclusion Criteria: * none Approximately 80 patients per year will be eligible for inclusion, as this is the number of patients that annually receive surgical treatment for PSM.
Where this trial is running
Oslo
- The Norwegian Radium Hospital — Oslo, Norway (Recruiting)
Study contacts
- Principal investigator: Kjersti Flatmark, MD PhD — Oslo University Hospital
- Study coordinator: Kjersti Flatmark, MD PhD
- Email: Kjersti.Flatmark@rr-research.no
- Phone: +47 22 93 40 00
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.